Developing an appropriate salt form for an active pharmaceutical ingredient

American Pharmaceutical Review

Volumn 12, Issue 7, 2009, Pages 62-65

  Brittain, Harry G ^a,b  

^a Center for Pharmaceutical Physics   (United States)

^b Pharmaceutical Technologies   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BASE; FAMOTIDINE; SALICYLIC ACID; SODIUM CHLORIDE;

ARTICLE; DRUG MANUFACTURE; DRUG SOLUBILITY; IONIZATION; METHODOLOGY; PKA;

EID: 74749083749     PISSN: 10998012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. SM Berge, LD Bighley, and DC Monkhouse. Pharmaceutical Salts. J. Pharm. Sci., 66: 1-19 (1977).
2. BD Anderson and KP Flora. Preparation of Water-Soluble Compounds Through Salt Formation. Chapter 34 in The Practice of Medicinal Chemistry, CG Wermuth, ed. Academic Press, New York, 1996, pp. 739-754.
3. PH Stahl and CG Wermuth. Handbook of Pharmaceutical Salts. Wiley-VCH, Weinheim, Germany, 2002.
4. LD Bighley, SM Berge, and DC Monkhouse. Salt Forms of Drugs and Absorption. in Encyclopedia of Pharmaceutical Technology, J Swarbrick and JC Boylan, eds. Marcel Dekker, New York, 1995, pp. 453-499.
5. EC Ware and DR Lu. An Automated Approach to Salt Selection for New Unique Trazodone Salts. Pharm. Res., 21: 177-184 (2004).
6. DA Haynes, W Jones, and WDS Motherwell. Occurrence of Pharmaceutically Acceptable Anions and Cations in the Cambridge Structural Database. J. Pharm. Sci., 94: 2111-2120 (2005).
7. PL Gould. Salt Selection for Basic Drugs. Int. J. Pharm., 33: 201-217 (1986).
8. KR Morris, MG Fakes, AB Thakur, AW Newman, AK Singh, JJ Venit, CJ Spagnuolo, and ATM Serajuddin. An Integrated Approach to the Selection of Optimal Salt Form for a New Drug Candidate. Int. J. Pharm., 105: 209-217 (1994).
9. W-Q Tong and G Whitesell. In Situ Salt Screening - A Useful Technique for Discovery Support and Preformulation Studies. Pharm. Dev. Tech., 3: 215-223 (1998).
10. M Sacchetti. General Equations for In Situ Salt Screening of Multibasic Drugs in Multiprotic Acids. Pharm. Dev. Tech., 5: 579-582 (2000).
11. RJ Bastin, MJ Bowker, and BJ Slater. Salt Selection and Optimization Procedures for Pharmaceutical New Chemical Entities. Org. Proc. Res. Dev., 4: 427-435 (2000).
12. ATM Serajuddin and M Pudipeddi. Salt-Selection Strategies, chapter 6 in Handbook of Pharmaceutical Salts, PH Stahl and CG Wermuth, eds. Wiley-VCH, Weinheim, Germany, 2002, pp. 135-160.
13. MJ Bowker. A Procedure for Salt Selection and Optimization. chapter 7 in Handbook of Pharmaceutical Salts, PH Stahl and CG Wermuth, eds. Wiley-VCH, Weinheim, Germany, 2002, pp. 161-189.
14. RB Hammond, RS Hashim, C Ma, and KJ Roberts. Grid-Based Molecular Modeling for Pharmaceutical Salt Screening: Case Example of 3,4,5,7,8,9- hexahydro-2H-pyrimido-(1,2-a)-primidinium acetate. J. Pharm. Sci., 95: 2361-2372 (2006).
15. HG Brittain. Strategy for the Prediction and Selection of Drug Substance Salt Forms. Pharm. Tech., 31(10): 78-88 (2007).
16. RJ Prankerd. Critical Compilation of pKA Values for Pharmaceutical Substances. in Profiles of Drug Substances Excipients, and Related Methodology, HG Brittain, ed. Elsevier-Academic Press, Amsterdam, 2007, p 191.
17. MJ O'Neil, PE Heckelman, CB Koch, and KJ.Roman Famotidine; entry 3930. in The Merck Index. Merck & Co., Whitehouse Station, 2006, p 3935.